Jeff Jones
Stock Analyst at Oppenheimer
(1.96)
# 3,183
Out of 5,090 analysts
95
Total ratings
31.4%
Success rate
-3.16%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Reiterates: Outperform | $50 → $57 | $26.36 | +116.24% | 2 | Nov 14, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $7.99 | +75.22% | 11 | Oct 27, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $66.56 | -5.35% | 6 | Oct 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $2.48 | +908.06% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $10.70 | +395.33% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $24.21 | +81.74% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $8.31 | +200.84% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $3.87 | +339.28% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $8.85 | +92.20% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $40.24 | +113.72% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $4.01 | +348.88% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.78 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.39 | +569.46% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.30 | +3,361.54% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.48 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.07 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.74 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.29 | +1,062.79% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $7.64 | +24,441.88% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $5.35 | +20,460.75% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Nov 14, 2025
Reiterates: Outperform
Price Target: $50 → $57
Current: $26.36
Upside: +116.24%
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $7.99
Upside: +75.22%
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $66.56
Upside: -5.35%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $2.48
Upside: +908.06%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $10.70
Upside: +395.33%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $24.21
Upside: +81.74%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $8.31
Upside: +200.84%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $3.87
Upside: +339.28%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $8.85
Upside: +92.20%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $40.24
Upside: +113.72%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $4.01
Upside: +348.88%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.78
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.39
Upside: +569.46%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.30
Upside: +3,361.54%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $17.48
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.07
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.74
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.29
Upside: +1,062.79%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $7.64
Upside: +24,441.88%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $5.35
Upside: +20,460.75%